The Role of MIF-173GC Gene Polymorphism in the Susceptibility of Autoimmune Diseases

Abstract EN

Some certain genetic polymorphisms have been considered to implicate in the pathogenesis and progression of autoimmune diseases and may predispose to an early stage of general autoimmune susceptibility.

Recent studies have been conducted to investigate the association between macrophage migration inhibitory factor- (MIF-) 173G/C gene polymorphism and autoimmune diseases; however, the results were not exactly identical.

In the present study, a systematic review and meta-analysis of case-control studies was performed to estimate the relationship.

A comprehensive search of PubMed, Ebsco, EMbase, WanFang databases and CNKI was done.

Odds ratio (ORs) and corresponding 95% confidence intervals (CIs) were combined to pool the effect size.

The publication bias was examined by Begg’s funnel plots and Egger’s test.

RevMan 5.3 and STATA 12.0 software were used for statistical processing.

23 papers were included, and the results revealed that MIF-173G/C was significantly associated with an increased risk of autoimmune diseases in five genetic models (recessive genetic model: OR=1.95, 95% CI: 1.52-2.50; dominant genetic model: OR=1.35, 95% CI: 1.24-1.46; allele model: OR=1.32, 95% CI: 1.23-1.41; homozygote model: OR=1.92, 95% CI: 1.57-2.35; heterozygote model: OR=4.92, 95% CI: 4.03-6.02), whether in Asia, Europe, or North America.

Furthermore, subgroup analysis showed an increasing risk in rheumatoid arthritis (RA), ulcerative colitis (UC), Crohn’s disease (CD), atopic dermatitis (AD), Henoch-Schonlein purpura (HSP), and Henoch-Schonlein purpura nephritis (HSPN), but it was not related to the susceptibility of autoimmune hepatitis (AIH).

Therefore, it could be considered that MIF-173G/C polymorphism could increase the susceptibility of autoimmune diseases, while there may be the discrepancy of disease entity.